CY1119377T1 - Φαρμακευτικη συνθεση - Google Patents

Φαρμακευτικη συνθεση

Info

Publication number
CY1119377T1
CY1119377T1 CY20171100990T CY171100990T CY1119377T1 CY 1119377 T1 CY1119377 T1 CY 1119377T1 CY 20171100990 T CY20171100990 T CY 20171100990T CY 171100990 T CY171100990 T CY 171100990T CY 1119377 T1 CY1119377 T1 CY 1119377T1
Authority
CY
Cyprus
Prior art keywords
pharmaceutical composition
carbonyl
tetrahydrothiazolo
ethanediamide
chloropyridin
Prior art date
Application number
CY20171100990T
Other languages
Greek (el)
English (en)
Inventor
Masazumi Kojima
Yoshio Kuno
Hiroaki Nakagami
Shinji Sagasaki
Koichi Ishidoh
Gaku Sekiguchi
Original Assignee
Daiichi Sankyo Company, Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39875378&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1119377(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Daiichi Sankyo Company, Limited filed Critical Daiichi Sankyo Company, Limited
Publication of CY1119377T1 publication Critical patent/CY1119377T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CY20171100990T 2007-03-29 2017-09-20 Φαρμακευτικη συνθεση CY1119377T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007087327 2007-03-29
PCT/JP2008/000791 WO2008129846A1 (ja) 2007-03-29 2008-03-28 医薬組成物

Publications (1)

Publication Number Publication Date
CY1119377T1 true CY1119377T1 (el) 2018-02-14

Family

ID=39875378

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20171100990T CY1119377T1 (el) 2007-03-29 2017-09-20 Φαρμακευτικη συνθεση

Country Status (28)

Country Link
US (3) US20100081685A1 (https=)
EP (1) EP2140867B2 (https=)
JP (2) JP4463875B2 (https=)
KR (1) KR101424843B1 (https=)
CN (2) CN101652139A (https=)
AU (1) AU2008241982B2 (https=)
BR (1) BRPI0809205B8 (https=)
CA (1) CA2680039C (https=)
CO (1) CO6220955A2 (https=)
CY (1) CY1119377T1 (https=)
DK (1) DK2140867T4 (https=)
ES (1) ES2644803T5 (https=)
FI (1) FI2140867T4 (https=)
HR (1) HRP20171384T4 (https=)
HU (2) HUE035990T2 (https=)
IL (2) IL200790A (https=)
LT (2) LT2140867T (https=)
MX (2) MX351987B (https=)
MY (1) MY149356A (https=)
NO (1) NO20093008L (https=)
NZ (2) NZ597109A (https=)
PL (1) PL2140867T5 (https=)
PT (1) PT2140867T (https=)
SG (1) SG179497A1 (https=)
SI (1) SI2140867T2 (https=)
TW (1) TWI409064B (https=)
WO (1) WO2008129846A1 (https=)
ZA (2) ZA200906182B (https=)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG179497A1 (en) 2007-03-29 2012-04-27 Daiichi Sankyo Co Ltd Pharmaceutical composition
SI2371830T1 (sl) 2008-12-17 2014-01-31 Daiichi Sankyo Company, Limited Postopek za pridobivanje diaminskih derivatov
JPWO2010071164A1 (ja) * 2008-12-19 2012-05-31 第一三共株式会社 活性化血液凝固第Ｘ因子（ＦＸａ）阻害剤
EP2383272A4 (en) 2009-01-13 2012-07-25 Daiichi Sankyo Co Ltd ACTIVE BLOOD CREATION FACTOR HEMMER
EP2407457B1 (en) 2009-03-10 2015-04-22 Daiichi Sankyo Company, Limited Process for producing diamine derivative
JP5652879B2 (ja) 2009-03-13 2015-01-14 第一三共株式会社 光学活性なジアミン誘導体の製造方法
AU2010242308A1 (en) * 2009-04-30 2011-12-01 Takeda Pharmaceutical Company Limited Solid preparation
TW201102064A (en) * 2009-06-18 2011-01-16 Daiichi Sankyo Co Ltd Pharmaceutical composition having improved dissolution property
ES2706880T3 (es) * 2010-02-22 2019-04-01 Daiichi Sankyo Co Ltd Preparación sólida de liberación sostenida para uso oral
JP5714562B2 (ja) * 2010-02-22 2015-05-07 第一三共株式会社 経口用徐放性固形製剤
JP5870023B2 (ja) * 2010-02-22 2016-02-24 第一三共株式会社 経口用徐放性固形製剤
JP5692873B2 (ja) * 2010-03-19 2015-04-01 第一三共株式会社 ジアミン誘導体の結晶およびその製造方法
WO2011115067A1 (ja) 2010-03-19 2011-09-22 第一三共株式会社 抗凝固剤の溶出改善方法
EP2589590B1 (en) 2010-07-02 2016-12-28 Daiichi Sankyo Company, Limited Process for preparation of optically active diamine derivative salt
ES2673182T3 (es) * 2011-08-10 2018-06-20 Daiichi Sankyo Company, Limited Composición farmacéutica que contiene un derivado de diamina
WO2013026553A1 (en) 2011-08-22 2013-02-28 Ratiopharm Gmbh Composition comprising edoxaban
CA2883077C (en) 2012-09-03 2017-03-07 Daiichi Sankyo Company, Limited Hydromorphone hydrochloride-containing oral sustained-release pharmaceutical composition
JP6227352B2 (ja) * 2012-09-27 2017-11-08 株式会社三和化学研究所 アナグリプチン又はその塩を含有する固形製剤
EP2952196A4 (en) * 2013-01-31 2016-08-03 Sawai Seiyaku Kk MULTILAYER TABLET WITH TELMISARTAN AND HYDROCHLOROTHIAZIDE
TW201521794A (zh) * 2013-11-12 2015-06-16 Daiichi Sankyo Co Ltd 錠劑
US20170022220A1 (en) * 2014-02-25 2017-01-26 Daiichi Sankyo Company, Limited High-purity crystals of active blood coagulation factor x (fxa) inhibitor
US20170368037A1 (en) * 2014-12-26 2017-12-28 Daiichi Sankyo Company, Limited Pharmaceutical composition for promotion of fibrinolysis
CN107405342B (zh) * 2015-12-24 2021-05-14 江苏恒瑞医药股份有限公司 一种含有二胺衍生物或其盐的固体药物组合物
US20190364946A1 (en) * 2016-03-16 2019-12-05 Omegatri As Powders and tablets comprising omega-3 fatty acid derivatives and methods for their production
JP6673798B2 (ja) * 2016-10-12 2020-03-25 日本化薬株式会社 カペシタビンを有効成分とするフィルムコート医薬製剤
TWI812602B (zh) 2016-12-01 2023-08-21 日商第一三共股份有限公司 含二胺衍生物之口腔崩散錠及其製造方法
TWI826474B (zh) 2018-06-27 2023-12-21 日商第一三共股份有限公司 包含二胺衍生物之顆粒劑、以及其用途及製造方法
KR102222774B1 (ko) * 2018-07-27 2021-03-04 보령제약 주식회사 에독사반을 포함하는 약학적 제제 및 이의 제조방법
KR20200079957A (ko) 2018-12-26 2020-07-06 한국콜마주식회사 에독사반을 함유한 경구용 의약 조성물 및 그의 제조방법
KR102514961B1 (ko) 2019-03-05 2023-03-28 주식회사 파마코스텍 에독사반 벤젠술폰산염 1 수화물 결정형 및 그 제조방법
EP3744320A1 (en) 2019-05-29 2020-12-02 Alfred E. Tiefenbacher (GmbH & Co. KG) Pharmaceutical tablet composition comprising edoxaban
KR20210048632A (ko) 2019-10-23 2021-05-04 한미약품 주식회사 에독사반 유리 염기 함유 제약 조성물
KR102333564B1 (ko) 2019-11-28 2021-12-01 동방에프티엘(주) 광학 활성 다이아민 유도체 및 티아졸 유도체의 생산을 위한 새로운 합성경로
KR102090912B1 (ko) 2019-12-18 2020-03-18 유니셀랩 주식회사 신규한 결정형 형태의 에독사반 및 이의 제조방법
EP3838267A1 (en) 2019-12-19 2021-06-23 Biohorm, S.L. Edoxaban tablets
KR102513519B1 (ko) 2020-06-08 2023-03-23 주식회사 파마코스텍 신규한 에독사반 벤젠술폰산염 1 수화물의 제조방법
KR102222784B1 (ko) 2020-09-17 2021-03-04 유니셀랩 주식회사 신규한 에독사반 헤미에틸렌다이설퍼닉산 염 일수화물
WO2022129535A1 (en) 2020-12-18 2022-06-23 Krka, D.D., Novo Mesto Edoxaban formulation containing no sugar alcohols
JP2022113667A (ja) * 2021-01-25 2022-08-04 全星薬品工業株式会社 エドキサバン含有医薬組成物
JP2023056113A (ja) * 2021-10-07 2023-04-19 日医工株式会社 エドキサバン含有医薬組成物
KR102518204B1 (ko) 2022-02-18 2023-04-05 주식회사 엔비피헬스케어 신규한 에독사반 프로필렌글리콜 용매화물
EP4629970A1 (en) 2022-12-09 2025-10-15 Synthon B.V. Formulation comprising edoxaban and preparation thereof
JP7352248B1 (ja) * 2023-03-27 2023-09-28 学校法人藤田学園 抗がん剤

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4361545A (en) * 1979-05-21 1982-11-30 Rowell Laboratories, Inc. Solid pharmaceutical formulations for slow, zero order release via controlled surface erosion
JP2814513B2 (ja) * 1988-02-03 1998-10-22 吉富製薬株式会社 溶出性の改良された製剤組成物
JP2642486B2 (ja) * 1989-08-04 1997-08-20 田辺製薬株式会社 難溶性薬物の超微粒子化法
US5149855A (en) 1989-12-26 1992-09-22 Mitsubishi Rayon Co., Ltd. Process for racemizing optically active carboxylic acid esters
US5055600A (en) 1990-04-24 1991-10-08 Rockwell International Corporation Glycidyl azide polymer (gap) synthesis by molten salt method
US5506248A (en) 1993-08-02 1996-04-09 Bristol-Myers Squibb Company Pharmaceutical compositions having good dissolution properties
IL110376A (en) * 1993-08-02 1998-08-16 Bristol Myers Squibb Co Pharmaceutical compositions containing ifetroban salts and methods for the preparation thereof
US5677469A (en) 1995-05-18 1997-10-14 Sepracor, Inc. Process for resolving chiral acids with 1-aminoindan-2-ols
JPH09309829A (ja) * 1996-05-22 1997-12-02 Taiyo Yakuhin Kogyo Kk ニトレンジピン含有経口投与製剤およびその製造法
EP0839526A3 (en) * 1996-10-31 1999-01-07 Takeda Chemical Industries, Ltd. Solid pharmaceutical preparation with fast buccal disintegration or dissolution
JPH11180899A (ja) 1997-12-15 1999-07-06 Mitsui Chem Inc 活性メチレンアルキル化化合物の製造法
JP3680203B2 (ja) 1999-06-01 2005-08-10 東洋化成工業株式会社 ４−アセチルアミノベンゼンスルホニルアジドの製造方法
JP2001151724A (ja) 1999-11-19 2001-06-05 Kuraray Co Ltd 光学活性な２，２，４−トリメチル−３−シクロヘキセンカルボン酸の製造方法
JP4044709B2 (ja) 1999-11-19 2008-02-06 信越化学工業株式会社 水系フィルムコーティング剤及び経口固形製剤
TWI290136B (en) 2000-04-05 2007-11-21 Daiichi Seiyaku Co Ethylenediamine derivatives
RU2271805C2 (ru) 2000-10-24 2006-03-20 Адзиномото Ко., Инк. Препарат, содержащий натеглинид
US20020160048A1 (en) * 2001-02-15 2002-10-31 Karoline Bechtold-Peters Medical formulation containing a muscarinic agonist
DE10106971A1 (de) 2001-02-15 2002-08-29 Boehringer Ingelheim Pharma Arzneimittelformulierung die einen muskarinischen Agonisten enthält
US7365205B2 (en) * 2001-06-20 2008-04-29 Daiichi Sankyo Company, Limited Diamine derivatives
JP4128138B2 (ja) 2001-06-20 2008-07-30 第一三共株式会社 ジアミン誘導体
KR100908418B1 (ko) * 2001-06-20 2009-07-21 액티버스 파마 컴퍼니 리미티드 퀴놀리논 유도체 의약 조성물 및 그의 제조 방법
JP3939601B2 (ja) * 2001-06-20 2007-07-04 株式会社アクティバスファーマ キノリノン誘導体医薬組成物及びその製造方法
PL368402A1 (en) 2001-08-09 2005-03-21 Daiichi Pharmaceutical Co, Ltd. Diamine derivatives
MY140561A (en) * 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
TW200306868A (en) * 2002-05-22 2003-12-01 Shionogi & Co Composition of hardly soluble medicine with improved solubility
JP4109288B2 (ja) 2002-12-25 2008-07-02 第一三共株式会社 ジアミン誘導体
CA2521325C (en) * 2003-04-08 2010-09-14 Novartis Ag Solid pharmaceutical compositions comprising a s1p receptor agonist and a sugar alcohol
CN102166212A (zh) 2003-06-17 2011-08-31 协和发酵麒麟株式会社 使盐酸贝尼地平从片剂中迅速溶出的方法
JP4606258B2 (ja) * 2003-06-17 2011-01-05 協和発酵キリン株式会社 塩酸ベニジピン含有医薬組成物
CA2545730C (en) 2003-11-12 2014-07-08 Daiichi Pharmaceutical Co., Ltd. Process for producing thiazole derivative
DE10355461A1 (de) 2003-11-27 2005-06-23 Bayer Healthcare Ag Verfahren zur Herstellung einer festen, oral applizierbaren pharmazeutischen Zusammensetzung
AR057035A1 (es) 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
BRPI0615775B1 (pt) 2005-09-16 2021-08-10 Daiichi Sankyo Company, Limited Processos para a produção de compostos derivados de diamida oticamente ativos
JP4703333B2 (ja) 2005-09-26 2011-06-15 エヌ・ティ・ティ・ソフトウェア株式会社 電子メール処理プログラム
SG179497A1 (en) 2007-03-29 2012-04-27 Daiichi Sankyo Co Ltd Pharmaceutical composition
TW200909437A (en) 2007-06-21 2009-03-01 Daiichi Sankyo Co Ltd Process for the preparation of diamine-derivatives
BRPI0922434A2 (pt) 2008-12-12 2015-12-15 Daiichi Sankyo Co Ltd processo para produzir ácido carboxílico opticamente ativo
SI2371830T1 (sl) 2008-12-17 2014-01-31 Daiichi Sankyo Company, Limited Postopek za pridobivanje diaminskih derivatov
JPWO2010071164A1 (ja) 2008-12-19 2012-05-31 第一三共株式会社 活性化血液凝固第Ｘ因子（ＦＸａ）阻害剤
EP2383272A4 (en) 2009-01-13 2012-07-25 Daiichi Sankyo Co Ltd ACTIVE BLOOD CREATION FACTOR HEMMER
EP2407457B1 (en) 2009-03-10 2015-04-22 Daiichi Sankyo Company, Limited Process for producing diamine derivative
JP5652879B2 (ja) 2009-03-13 2015-01-14 第一三共株式会社 光学活性なジアミン誘導体の製造方法
WO2010131663A1 (ja) 2009-05-15 2010-11-18 第一三共株式会社 オキサミド誘導体
TW201102064A (en) 2009-06-18 2011-01-16 Daiichi Sankyo Co Ltd Pharmaceutical composition having improved dissolution property
JP2011051672A (ja) 2009-08-31 2011-03-17 Ihi Corp ラック棚及びラック棚の組立て方法
JP5692873B2 (ja) 2010-03-19 2015-04-01 第一三共株式会社 ジアミン誘導体の結晶およびその製造方法
US20130158069A1 (en) 2011-12-14 2013-06-20 Daiichi Sankyo Company, Limited Preventive and/or therapeutic agent for thromboembolism in thromboembolism patient with severe renal impairment

Also Published As

Publication number Publication date
CO6220955A2 (es) 2010-11-19
US20130337064A1 (en) 2013-12-19
ES2644803T5 (es) 2024-02-26
LTC2140867I2 (lt) 2018-11-12
LTPA2018005I1 (lt) 2018-02-12
PL2140867T3 (pl) 2017-12-29
NZ579725A (en) 2012-02-24
MX351987B (es) 2017-11-03
MX2009010474A (es) 2009-10-19
DK2140867T4 (da) 2023-09-25
CA2680039C (en) 2015-05-26
SG179497A1 (en) 2012-04-27
US9707296B2 (en) 2017-07-18
US20150342938A1 (en) 2015-12-03
ZA201005906B (en) 2012-05-30
US9149532B2 (en) 2015-10-06
JP2010090168A (ja) 2010-04-22
BRPI0809205B8 (pt) 2021-05-25
JPWO2008129846A1 (ja) 2010-07-22
RU2009139917A (ru) 2011-05-10
ZA200906182B (en) 2010-11-24
EP2140867B2 (en) 2023-08-16
MY149356A (en) 2013-08-30
BRPI0809205B1 (pt) 2019-09-03
AU2008241982A1 (en) 2008-10-30
WO2008129846A1 (ja) 2008-10-30
CA2680039A1 (en) 2008-10-30
IL200790A (en) 2014-06-30
EP2140867B1 (en) 2017-08-30
SI2140867T2 (sl) 2023-10-30
HRP20171384T1 (hr) 2017-11-17
BRPI0809205A2 (pt) 2014-09-02
RU2470637C2 (ru) 2012-12-27
IL219829A0 (en) 2012-06-28
JP4463875B2 (ja) 2010-05-19
CN104324015B (zh) 2018-08-28
HRP20171384T4 (hr) 2024-02-16
CN101652139A (zh) 2010-02-17
DK2140867T3 (en) 2017-10-09
TWI409064B (zh) 2013-09-21
HUE035990T2 (en) 2018-05-28
AU2008241982B2 (en) 2013-02-21
EP2140867A4 (en) 2013-07-03
ES2644803T3 (es) 2017-11-30
TW200845972A (en) 2008-12-01
IL200790A0 (en) 2010-05-17
NO20093008L (no) 2009-09-30
KR101424843B1 (ko) 2014-08-13
NZ597109A (en) 2013-01-25
SI2140867T1 (sl) 2017-12-29
PT2140867T (pt) 2017-10-04
PL2140867T5 (pl) 2023-10-30
US20100081685A1 (en) 2010-04-01
CN104324015A (zh) 2015-02-04
HUS1800007I1 (hu) 2018-03-28
EP2140867A1 (en) 2010-01-06
KR20090122950A (ko) 2009-12-01
LT2140867T (lt) 2017-12-11
FI2140867T4 (fi) 2023-09-14

Similar Documents

Publication Publication Date Title
CY1119377T1 (el) Φαρμακευτικη συνθεση
FIC20210022I1 (fi) tukatinibi, valinnaisesti farmaseuttisesti hyväksyttävän suolan tai solvaatin muodossa
CR10072A (es) Derivados de pirimidinil-aril-urea que son inhibidores de fgf
EA201000886A1 (ru) Органические соединения
UA87153C2 (ru) Энантиомерно чистые аминогетероарильные соединения как ингибиторы протеинкиназы
CY1109998T1 (el) Ενδυναμωτες υποδοχεων γλουταμινικου
DK1853602T3 (da) Kemiske forbindelser
CY1108275T1 (el) Χημικες ενωσεις
NO2014009I2 (no) Forbindelser, farmasøytiske sammensetninger og anvendelser derav, samt fremgangsmåte for å fremstille nevnte forbindelser
SE0302811D0 (sv) Novel compounds
CY1110419T1 (el) Τρικυκλικες ενωσεις με βαση το 1,6-διυδρο-1,3,5,6-tetpaaza-as-ινδακενιο και φαρμακευτικες συνθεσεις που τις περιεχουν ως αναστολεις της ενζυμικης ενεργοτητας της ικκ
CY1110137T1 (el) Συμπυκνωμενες τρικυκλικες ενωσεις peri χρησιμες ως αντιβακτηριακοι παραγοντες
CY1109916T1 (el) Βενζιμιδαζολο-θειοφαινικες ενωσεις ως plk αναστολεις
BRPI0514372A (pt) inibidores de tiazol de frutose 1, 6-bisfosfatase
CL2008000021A1 (es) Compuestos derivados de 2,4-dianilinopirimidinas, inhibidores de proteinas cinasas; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento o prevencion de enfermedades inflamatorias, diabetes y cancer.
BRPI0618451A2 (pt) derivados de piridopirazina, seu uso, composição farmacêutica e estojo
BRPI0714885B8 (pt) compostos terapêuticos e seu uso
CY1109962T1 (el) Υποκατεστημενες ενωσεις 1,4,8-τριαζασπειρο[4,5]δεκαν-2-ονης για τη θεραπεια παχυσαρκιας
BRPI0413151A (pt) derivados de amino propanol
CY1112960T1 (el) Παραγωγα ουριας, μεθοδοι για την παρασκευη τους και χρησεις αυτων
CY1113257T1 (el) Παραγωγα βενζυλοπιπεραζινης τα οποια ειναι χρησιμα στη θεραπεια γαστρεντερικων διαταραχων
ECSP066883A (es) Derivados de heteroarilaminopirazol utiles para el tratamiento de la diabetes
DOP2005000025A (es) Compuestos de heteroaril- y fenilsulfamoilo sustituidos
BR0314352A (pt) Indóis 2,7-substituìdos e seu uso como moduladores de 5-ht6
BRPI0509660A (pt) compostos de beta-carbolina de utilidade no tratamento de doenças inflamatórias